Wir überwinden Grenzen

(February 6, 2026) The Medical Center – University of Freiburg will remain a clinical partner in the nanodiag BW future cluster, which has been awarded a second three-year funding phase in the Clusters4Future program. Joint research will continue from April 2026.

nanodiag BW focuses on molecular diagnostics using nanopore technology. The aim is to reliably visualize disease-related changes at the smallest level – for example, in cancer or other complex diseases. Around €1.1 million in funding

has been earmarked for the Medical Center – University of Freiburg. Clinical chairs, including those in oncology and medical epigenetics, contribute their experience in research and care.

One focus is on gentle diagnostic procedures such as liquid biopsy. This involves obtaining information about the disease from blood, for example, without surgical intervention. This allows diseases and therapy courses to be examined in a way that is less stressful for patients.
  

Further interesting articles